Efficacy of EGFR TKIs of different generations in NSCLC with EGFR mutations: review of clinical studies and our experience
Kobziev O.I., Boiarskyi O.O., Leonova V.V.
Summary. In recent years, significant progress was achieved in the effective treatment of patients with non-small-cell lung cancer with an EGFR mutation. Currently, there are three generations of EGFR tyrosine kinase inhibitors (TKIs), characterized by different pharmacological characteristics and clinical profiles. We provide an overview of the development of EGFR TKI therapy. In this context, the third-generation EGFR TKI osimertinib deserves special attention, which has demonstrated a number of advantages in terms of the effectiveness and tolerability, as well as some indicators of the quality of life of patients. Clinical research data confirmed by our experience in routine clinical practice.
Leave a comment